ARTICLE | Company News

Takeda, Wave in CNS nucleic acid deal

February 23, 2018 3:23 PM UTC

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and Wave Life Sciences Ltd. (NASDAQ:WVE) partnered to develop and commercialize nucleic acid therapies to treat CNS diseases.

Wave will receive an upfront payment of $170 million, including $110 million in cash and $60 million through the purchase of shares at $54.70, where Wave's shares closed on Feb. 16 before the deal was announced...